After many years of research to identify new anti-inflammatory drugs, corticosteroids and NSAIDs (non-steroidal anti-inflammatory drugs) are still the main agents used to control inflammation. Many patients rotate through several of these due to insufficient efficacy, adverse side effects and/or use unproven complementary therapies.
Pre-clinical and clinical data of AKL’s investigational drug APPA has demonstrated its potential to reduce the pain associated with osteoarthritis (OA) and APPA’s ability to reduce cartilage degradation has also been demonstrated in an animal model
The APPA Phase II human trial of APPA in OA of the knee has been conducted at three sites in Denmark by AKLRD’s partner Nordic Bioscience Clinical Development (NBCD), following the successful completion of Phase I.
Despite Covid, the Phase II 150-patient placebo-controlled Human Efficacy Study of APPA in osteoarthritis of the knee has completed a month ahead of schedule and the last patient to enter the study completed their treatment on 16th April. The study is due to report in 4Q2021.
David Miles, CEO, says, “With patient recruitment ahead of plan, encouraging phase I data and an indication of APPA’s potential to reduce cartilage degradation in addition to relieving pain, we are looking forward to the results of this important study”.